+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Asia Pacific Theranostics Market Size, Share & Trends Analysis Report By End User, By Product (Radiopharmaceuticals, Diagnostic Imaging, IVD/Biomarker Screening, and Software & Services), By Application, By Country and Growth Forecast, 2023 - 2030

  • PDF Icon

    Report

  • 127 Pages
  • March 2024
  • Region: Asia Pacific
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5949409
The Asia Pacific Theranostics Market would witness market growth of 16.2% CAGR during the forecast period (2023-2030).

The China market dominated the Asia Pacific Theranostics Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $351.8 million by 2030. The Japan market is registering a CAGR of 15.6% during (2023 - 2030). Additionally, The India market would showcase a CAGR of 17% during (2023 - 2030).



Imaging modalities such as functional MRI (fMRI), diffusion tensor imaging (DTI), and amyloid PET imaging enable visualization of brain structure, function, and pathology, aiding in diagnosing and monitoring neurodegenerative diseases. Biomarker-based assays, including cerebrospinal fluid (CSF) analysis and neuroimaging markers, provide diagnostic and prognostic information for neurologic conditions. Theranostic approaches help identify therapeutic targets and guide personalized treatment strategies for neurological disorders, facilitating early intervention and disease modification.

Theranostics are increasingly being explored for diagnosing and managing infectious diseases, including bacterial, viral, and fungal infections. Diagnostic techniques such as nucleic acid amplification tests (NAATs), serological assays, and imaging modalities enable rapid and accurate detection of infectious agents and assessment of disease severity. Theranostic approaches help identify antimicrobial resistance patterns, guide antibiotic stewardship initiatives, and optimize antimicrobial therapy for infectious diseases.

The expansion of healthcare expenditure in Australia enables greater access to advanced diagnostic and therapeutic technologies, including these, for patients nationwide. According to data released by the Australian government, the nation spent an estimated $241.3 billion, or almost $9,365 per person, on health-related products and services in 2021-2022. The total amount spent on recurrent and capital health care increased by 6.0% in real terms (adjusted for inflation) compared to 2020-21. Thus, the increasing expenditure in the healthcare sector and the growing elderly population drive the market’s growth.

Based on End User, the market is segmented into Hospitals & Cancer Care Centers, Theranostics Centers, and Research & Academic Centers. Based on Product, the market is segmented into Radiopharmaceuticals, Diagnostic Imaging, IVD/Biomarker Screening, and Software & Services. Based on Application, the market is segmented into Prostate Cancer, Bone Metastasis, Other Cancers, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

  • Bayer AG
  • GE HealthCare Technologies, Inc.
  • Siemens Healthineers AG (Siemens AG)
  • Cardinal Health, Inc.
  • Canon, Inc.
  • Clarity Pharmaceuticals Ltd
  • Koninklijke Philips N.V.
  • Thermo Fisher Scientific, Inc.
  • Telix Pharmaceuticals Limited
  • ABX advanced biochemical compounds GmbH

Market Report Segmentation

By End User
  • Hospitals & Cancer Care Centers
  • Theranostics Centers
  • Research & Academic Centers
By Product
  • Radiopharmaceuticals
  • Diagnostic Imaging
  • IVD/Biomarker Screening
  • Software & Services
By Application
  • Prostate Cancer
  • Bone Metastasis
  • Other Cancers
  • Others
By Country
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Theranostics Market, by End User
1.4.2 Asia Pacific Theranostics Market, by Product
1.4.3 Asia Pacific Theranostics Market, by Application
1.4.4 Asia Pacific Theranostics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter’s Five Forces Analysis
Chapter 4. Asia Pacific Theranostics Market by End User
4.1 Asia Pacific Hospitals & Cancer Care Centers Market by Country
4.2 Asia Pacific Theranostics Centers Market by Country
4.3 Asia Pacific Research & Academic Centers Market by Country
Chapter 5. Asia Pacific Theranostics Market by Product
5.1 Asia Pacific Radiopharmaceuticals Market by Country
5.2 Asia Pacific Diagnostic Imaging Market by Country
5.3 Asia Pacific IVD/Biomarker Screening Market by Country
5.4 Asia Pacific Software & Services Market by Country
Chapter 6. Asia Pacific Theranostics Market by Application
6.1 Asia Pacific Prostate Cancer Market by Country
6.2 Asia Pacific Bone Metastasis Market by Country
6.3 Asia Pacific Other Cancers Market by Country
6.4 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Theranostics Market by Country
7.1 China Theranostics Market
7.1.1 China Theranostics Market by End User
7.1.2 China Theranostics Market by Product
7.1.3 China Theranostics Market by Application
7.2 Japan Theranostics Market
7.2.1 Japan Theranostics Market by End User
7.2.2 Japan Theranostics Market by Product
7.2.3 Japan Theranostics Market by Application
7.3 India Theranostics Market
7.3.1 India Theranostics Market by End User
7.3.2 India Theranostics Market by Product
7.3.3 India Theranostics Market by Application
7.4 South Korea Theranostics Market
7.4.1 South Korea Theranostics Market by End User
7.4.2 South Korea Theranostics Market by Product
7.4.3 South Korea Theranostics Market by Application
7.5 Singapore Theranostics Market
7.5.1 Singapore Theranostics Market by End User
7.5.2 Singapore Theranostics Market by Product
7.5.3 Singapore Theranostics Market by Application
7.6 Malaysia Theranostics Market
7.6.1 Malaysia Theranostics Market by End User
7.6.2 Malaysia Theranostics Market by Product
7.6.3 Malaysia Theranostics Market by Application
7.7 Rest of Asia Pacific Theranostics Market
7.7.1 Rest of Asia Pacific Theranostics Market by End User
7.7.2 Rest of Asia Pacific Theranostics Market by Product
7.7.3 Rest of Asia Pacific Theranostics Market by Application
Chapter 8. Company Profiles
8.1 Bayer AG
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 GE HealthCare Technologies, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Segmental and Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Partnerships, Collaborations, and Agreements:
8.2.6 SWOT Analysis
8.3 Siemens Healthineers AG (Siemens AG)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Product Launches and Product Expansions:
8.3.6 SWOT Analysis
8.4 Cardinal Health, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 SWOT Analysis
8.5 Canon, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 SWOT Analysis
8.6 Clarity Pharmaceuticals Ltd
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Research & Development Expenses
8.6.4 SWOT Analysis
8.7 Koninklijke Philips N.V.
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expense
8.7.5 SWOT Analysis
8.8 Thermo Fisher Scientific, Inc.
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 SWOT Analysis
8.9 Telix Pharmaceuticals Limited
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 SWOT Analysis
8.10. ABX advanced biochemical compounds GmbH
8.10.1 Company Overview
8.10.2 SWOT Analysis

Companies Mentioned

  • Bayer AG
  • GE HealthCare Technologies, Inc.
  • Siemens Healthineers AG (Siemens AG)
  • Cardinal Health, Inc.
  • Canon, Inc.
  • Clarity Pharmaceuticals Ltd
  • Koninklijke Philips N.V.
  • Thermo Fisher Scientific, Inc.
  • Telix Pharmaceuticals Limited
  • ABX advanced biochemical compounds GmbH

Methodology

Loading
LOADING...